TVTX — Travere Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual cashflow statement for Travere Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-169	-180	-278	-111	-322
Depreciation
Non-Cash Items	127	58.7	58.2	-182	104
Discontinued Operations
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-25.2	80	0.904	-25.5	-63
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-42.7	-14.8	-186	-280	-237
Capital Expenditures	-24.6	-24.2	-28.6	-42.3	-101
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-36.8	-113	-4	98	201
Acquisition of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-61.3	-138	-32.6	55.8	99.3
Financing Cash Flow Items	-7.7	-6.09	-11.5	-0.316	0.232
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	128	232	118	219	139
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	22.3	81	-104	-3.51	0.359